NEW YORK, NY / ACCESSWIRE / July 16, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
CytomX Therapeutics, Inc. (CTMX)
Investors Affected: May 17, 2018 - May 13, 2020
A class action has commenced on behalf of certain shareholders in CytomX Therapeutics, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) CytomX had downplayed issues with CX-072's efficacy observed in the PROCLAIM-CX-072 clinical program; (ii) CytomX had similarly downplayed issues with CX-2009's efficacy and safety observed in the PROCLAIM-CX-2009 clinical program; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/cytomx-therapeutics-inc-loss-submission-form/?id=7997&from=1
Endo International Plc (ENDP)
Investors Affected: August 8, 2017 - June 10, 2020
A class action has commenced on behalf of certain shareholders in Endo International Plc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Endo's and/or its subsidiaries' contributions to the opioid crisis (including, but not limited to, their opioid products' disproportionately negative impact on New York and the fraud that Defendants perpetrated on the New York insurance market) were larger in scope than the Company had represented; (ii) part of that contribution to the crisis included Endo publishing and disseminating false information to health care providers regarding the risks and benefits of opioids; (iii) the foregoing, once revealed, was foreseeably likely to subject Endo and/or its subsidiaries to increased regulatory scrutiny and enforcement, as well as significant financial and/or reputational harm, particularly with respect to New York; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Shareholders may find more information at https://securitiesclasslaw.com/securities/endo-international-plc-loss-submission-form/?id=7997&from=1
Chembio Diagnostics, Inc. (CEMI)
Investors Affected: March 12, 2020 - June 16, 2020
A class action has commenced on behalf of certain shareholders in Chembio Diagnostics, Inc. According to the filed complaint, defendants engaged in a scheme to deceive the market and a course of conduct that artificially inflated Chembio's stock price and operated as a fraud or deceit by misrepresenting the efficacy of the Company's Dual Path Platform ("DPP") COVID-19 test. Defendants allegedly achieved this by making false statements about Chembio's DPP COVID-19 test, although they knew or at least recklessly disregarded that there were material performance concerns with the test. When defendants' prior misrepresentations were disclosed and became apparent to the market, the price of Chembio stock fell precipitously as the prior artificial inflation came out of Chembio's stock price.
Shareholders may find more information at https://securitiesclasslaw.com/securities/chembio-diagnostics-inc-loss-submission-form/?id=7997&from=1
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Phone: (212) 537-9430
Fax: (833) 862-7770
SOURCE: The Gross Law Firm
View source version on accesswire.com: